Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Scientists studying tuberculosis are struggling with scarce funds, layers of bureaucracy and a lack of markers that can clearly identify which treatments are working, reports Apoorva Mandavilli.
An orally available drug enters the brain and interferes with signaling of orexin neuropeptides—providing a potential treatment for sleep disorders and possibly addiction (pages 150–155).
The nuclear hormone receptor LXR—best known for sensing cholesterol metabolites—also responds to glucose. The findings give LXR a central role in modulating the body's response to metabolic inputs.